scholarly journals In Vitro Antiviral Activity of α-Mangostin against Dengue Virus Serotype-2 (DENV-2)

Molecules ◽  
2021 ◽  
Vol 26 (10) ◽  
pp. 3016
Author(s):  
Kingshuk Panda ◽  
Kalichamy Alagarasu ◽  
Poonam Patil ◽  
Megha Agrawal ◽  
Ashwini More ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Dengue Virus ◽  
Docking Studies ◽  
Immunofluorescence Assay ◽  
Protein Targets ◽  
Glycoprotein E ◽  
Antiviral Therapies ◽  
Virus Serotype ◽  
Ns3 Protease

Dengue virus (DENV), a member of the family Flaviviridae, is a threat for global health as it infects more than 100 million people yearly. Approved antiviral therapies or vaccines for the treatment or prevention of DENV infections are not available. In the present study, natural compounds were screened for their antiviral activity against DENV by in vitro cell line-based assay. α-Mangostin, a xanthanoid, was observed to exert antiviral activity against DENV-2 under pre-, co- and post-treatment testing conditions. The antiviral activity was determined by foci forming unit (FFU) assay, quantitative RT-PCR and cell-based immunofluorescence assay (IFA). A complete inhibition of DENV-2 was observed at 8 µM under the co-treatment condition. The possible inhibitory mechanism of α-Mangostin was also determined by docking studies. The molecular docking experiments indicate that α-Mangostin can interact with multiple DENV protein targets such as the NS5 methyltransferase, NS2B-NS3 protease and the glycoprotein E. The in vitro and in silico findings suggest that α-Mangostin possesses the ability to suppress DENV-2 production at different stages of its replication cycle and might act as a prophylactic/therapeutic agent against DENV-2.

scholarly journals Antiviral Activity of Isobutyl Gallate to Dengue Virus Serotype 2 In Vitro

2019 ◽  
Vol 251 ◽  
pp. 012018 ◽  
Author(s):  
B E Dewi ◽  
M Angelina ◽  
F Nuwwaaridya ◽  
H Desti ◽  
T M Sudiro
Keyword(s):  
Antiviral Activity ◽  
Dengue Virus ◽  
Virus Serotype ◽  
Dengue Virus Serotype 2

scholarly journals In vitro antiviral activity of spirotetronate compounds against dengue virus serotype 2

2019 ◽  
Vol 65 (4) ◽  
pp. 197-203 ◽  
Author(s):  
Jirayut Euanorasetr ◽  
Bungonsiri Intra ◽  
Nutthanit Thunmrongsiri ◽  
Jitra Limthongkul ◽  
Sukathida Ubol ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Dengue Virus ◽  
Virus Serotype ◽  
Dengue Virus Serotype 2

scholarly journals Micafungin Inhibits Dengue Virus Infection through the Disruption of Virus Binding, Entry, and Stability

2021 ◽  
Vol 14 (4) ◽  
pp. 338
Author(s):  
Yen-Chen Chen ◽  
Jeng-Wei Lu ◽  
Chia-Tsui Yeh ◽  
Te-Yu Lin ◽  
Feng-Cheng Liu ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Dengue Fever ◽  
Early Stage ◽  
Quantitative Polymerase Chain Reaction ◽  
Enterovirus 71 ◽  
Denv Infection ◽  
Immunofluorescence Assay ◽  
Dependent Manner ◽  
Virus Binding ◽  
Virus Serotype

Dengue fever is an arbovirus disease caused by infection with the dengue virus (DENV). Half of the world’s population lives under the threat of dengue fever, however, researchers have yet to develop any drugs that are clinically applicable to this infection. Micafungin is a member of the echinocandins family of anti-fungal drugs, capable of blocking the synthesis of β-1,3-D-glucan in the walls of fungal cells. Previous studies have demonstrated the effectiveness of Micafungin against infections of enterovirus 71 (EV71) and chikungunya virus (CHIKV). This is the first study demonstrating the effectiveness of micafungin in inhibiting the cytopathic effects of dengue virus serotype 2 (DENV-2) in a dose-dependent manner. Time-of-addition assays verified the inhibitory effects of micafungin in pre-treated, co-treated, and full-treatment groups. Binding and entry assays also demonstrated the effectiveness of micafungin in the early stage of DENV-2 infection. The virucidal efficacy of micafungin appears to lie in its ability to destroy the virion. Molecular docking assays revealed the binding of micafungin to the envelope protein of DENV-2, thereby revealing the mechanism by which micafungin affects the early stage of DENV infection and the stability of DENV. Two other micafungin analogs, caspofungin and anidulafungin, were also shown to have the antiviral effects on DENV-2. Finally, immunofluorescence assay (IFA) and reverse-transcription quantitative polymerase chain reaction (RT-qPCR) confirmed the broad anti-DENV ability of micafungin against dengue virus serotypes 1, 3, and 4 (DENV-1, DENV-3, and DENV-4). Taken together, these results demonstrate the potential of micafungin and its analogs as candidates for the development of broad-spectrum treatments for DENV infection.

scholarly journals Therapeutic Intervention of COVID-19 by Natural Products: A Population-Specific Survey Directed Approach

Molecules ◽  
2021 ◽  
Vol 26 (4) ◽  
pp. 1191
Author(s):  
Christian R. Gomez ◽  
Ingrid Espinoza ◽  
Fazlay S. Faruke ◽  
Mahbub Hasan ◽  
Khondaker Miraz Rahman ◽  
...  
Keyword(s):  
Natural Products ◽  
Critical Factor ◽  
Docking Studies ◽  
Therapeutic Interventions ◽  
Management Approach ◽  
Protein Targets ◽  
In Silico Docking ◽  
High Prevalence ◽  
Glucose 6 Phosphate Dehydrogenase

To date very few promising leads from natural products (NP) secondary metabolites with antiviral and immunomodulatory properties have been identified for promising/potential intervention for COVID-19. Using in-silico docking studies and genome based various molecular targets, and their in vitro anti-SARS CoV-2 activities against whole cell and/or selected protein targets, we select a few compounds of interest, which can be used as potential leads to counteract effects of uncontrolled innate immune responses, in particular those related to the cytokine storm. A critical factor for prevention and treatment of SARS-CoV-2 infection relates to factors independent of viral infection or host response. They include population-related variables such as concurrent comorbidities and genetic factors critically relevant to COVID-19 health disparities. We discuss population risk factors related to SARS-CoV-2. In addition, we focus on virulence related to glucose-6-phosphate dehydrogenase deficiency (G6PDd), the most common human enzymopathy. Review of data on the response of individuals and communities with high prevalence of G6PDd to NP, prompts us to propose the rationale for a population-specific management approach to rationalize design of therapeutic interventions of SARS-CoV-2 infection, based on use of NP. This strategy may lead to personalized approaches and improve disease-related outcomes.

scholarly journals Illustrating and homology modeling the proteins of the Zika virus

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 275 ◽  
Author(s):  
Sean Ekins ◽  
John Liebler ◽  
Bruno J. Neves ◽  
Warren G. Lewis ◽  
Megan Coffee ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Crystal Structures ◽  
Zika Virus ◽  
Antiviral Drug ◽  
Homology Model ◽  
Model Quality ◽  
Glycoprotein E ◽  
Starting Point ◽  
Homology Models

The Zika virus (ZIKV) is a flavivirus of the familyFlaviviridae, which is similar to dengue virus, yellow fever and West Nile virus. Recent outbreaks in South America, Latin America, the Caribbean and in particular Brazil have led to concern for the spread of the disease and potential to cause Guillain-Barré syndrome and microcephaly. Although ZIKV has been known of for over 60 years there is very little in the way of knowledge of the virus with few publications and no crystal structures. No antivirals have been tested against it eitherin vitroorin vivo. ZIKV therefore epitomizes a neglected disease. Several suggested steps have been proposed which could be taken to initiate ZIKV antiviral drug discovery using both high throughput screens as well as structure-based design based on homology models for the key proteins. We now describe preliminary homology models created for NS5, FtsJ, NS4B, NS4A, HELICc, DEXDc, peptidase S7, NS2B, NS2A, NS1, E stem, glycoprotein M, propeptide, capsid and glycoprotein E using SWISS-MODEL. Eleven out of 15 models pass our model quality criteria for their further use. While a ZIKV glycoprotein E homology model was initially described in the immature conformation as a trimer, we now describe the mature dimer conformer which allowed the construction of an illustration of the complete virion. By comparing illustrations of ZIKV based on this new homology model and the dengue virus crystal structure we propose potential differences that could be exploited for antiviral and vaccine design. The prediction of sites for glycosylation on this protein may also be useful in this regard. While we await a cryo-EM structure of ZIKV and eventual crystal structures of the individual proteins, these homology models provide the community with a starting point for structure-based design of drugs and vaccines as well as a for computational virtual screening.

scholarly journals Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451

2013 ◽  
Vol 58 (2) ◽  
pp. 647-653 ◽  
Author(s):  
Huiling Yang ◽  
Margaret Robinson ◽  
Amoreena C. Corsa ◽  
Betty Peng ◽  
Guofeng Cheng ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Activity ◽  
Protease Inhibitor ◽  
Hcv Infection ◽  
Cross Resistance ◽  
Protease Gene ◽  
Ns5a Inhibitor ◽  
Ns3 Protease

ABSTRACTGS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1 (GT1) HCV infection. Key preclinical properties of GS-9451, includingin vitroantiviral activity, selectivity, cross-resistance, and combination activity, as well as pharmacokinetic properties, were determined. In multiple GT1a and GT1b replicon cell lines, GS-9451 had mean 50% effective concentrations (EC50s) of 13 and 5.4 nM, respectively, with minimal cytotoxicity; similar potency was observed in chimeric replicons encoding the NS3 protease gene of GT1 clinical isolates. GS-9451 was less active in GT2a replicon cells (EC50= 316 nM). Additive to synergisticin vitroantiviral activity was observed when GS-9451 was combined with other agents, including alpha interferon, ribavirin, and the polymerase inhibitors GS-6620 and tegobuvir (GS-9190), as well as the NS5A inhibitor ledipasvir (GS-5885). GS-9451 retained wild-type activity against multiple classes of NS5B and NS5A inhibitor resistance mutations. GS-9451 was stable in hepatic microsomes and hepatocytes from human and three other tested species. Systemic clearance was low in dogs and monkeys but high in rats. GS-9451 showed good oral bioavailability in all three species tested. In rats, GS-9451 levels were ∼40-fold higher in liver than plasma after intravenous dosing, and elimination of GS-9451 was primarily through biliary excretion. Together, these results are consistent with the antiviral activity observed in a recent phase 1b study. The results ofin vitrocross-resistance and combination antiviral assays support the ongoing development of GS-9451 in combination with other agents for the treatment of chronic HCV infection.

The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell

2005 ◽  
Vol 66 (2-3) ◽  
pp. 103-110 ◽  
Author(s):  
L TALARICO ◽  
C PUJOL ◽  
R ZIBETTI ◽  
P FARIA ◽  
M NOSEDA ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Dengue Virus ◽  
Host Cell ◽  
Sulfated Polysaccharides ◽  
Virus Serotype

scholarly journals Antiviral Activity of Novel Quinoline Derivatives against Dengue Virus Serotype 2

Molecules ◽  
2018 ◽  
Vol 23 (3) ◽  
pp. 672 ◽  
Author(s):  
Carolina de la Guardia ◽  
David Stephens ◽  
Hang Dang ◽  
Mario Quijada ◽  
Oleg Larionov ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Dengue Virus ◽  
Quinoline Derivatives ◽  
Virus Serotype ◽  
Dengue Virus Serotype 2

scholarly journals Drug of Action Cassia Alata Leaves Extract as Antiviral to Dengue Virus Serotype-2 in vitro

2020 ◽  
Vol 12 (4) ◽  
pp. 864-871
Author(s):  
Marissa Angelina ◽  
Muhammad Hanafi ◽  
Franciscus D Suyatna ◽  
Beti Ernawati Dewi
Keyword(s):  
Dengue Virus ◽  
Cassia Alata ◽  
Virus Serotype ◽  
Dengue Virus Serotype 2
Sign in / Sign up

Export Citation Format

Share Document